Novacyt Stock

Novacyt Profit per Employee

The Profit per Employee of Novacyt (ALNOV.PA) as of Aug 11, 2026 is -350,907.56 GBP. In the previous year, Profit per Employee was -237,747.90 GBP — a change of 47.60% (lower).

Profit per Employee

-350,907.56GBP

YoY

47.60%

Last updated:

Profit per Employee of Novacyt is 2026 -350,907.56 GBP. Profit per Employee of Novacyt was 2025 -237,747.90 GBP. It decreases by 47.60% lower compared to the previous year.
Access this data via the Eulerpool API

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

Profit per Employee of Novacyt is -350,907.56 GBP in 2026.

Profit per Employee of Novacyt changed from -237,747.90 GBP to -350,907.56 GBP, representing a 47.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Profit per Employee Novacyt since 2006 – with annual values, charts, and detailed analysis.

Profit per employee measures how much net income each employee generates on average. It is a key indicator of workforce efficiency.

Profit per Employee's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Profit per Employee's Novacyt historically and in real time.

Access this data via the Eulerpool API

Workforce — Novacyt

All Key Metrics — Novacyt